Equities research analysts forecast that Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) will post sales of $22.13 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Aurinia Pharmaceuticals’ earnings. The highest sales estimate is $26.70 million and the lowest is $15.50 million. Aurinia Pharmaceuticals reported sales of $910,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 2,331.9%. The business is expected to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $144.87 million for the current financial year, with estimates ranging from $121.37 million to $159.60 million. For the next financial year, analysts anticipate that the business will post sales of $269.33 million, with estimates ranging from $227.47 million to $310.50 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last announced its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.01. Aurinia Pharmaceuticals had a negative net margin of 396.81% and a negative return on equity of 48.92%. The business had revenue of $23.40 million for the quarter, compared to analyst estimates of $22.43 million. During the same period last year, the business earned ($0.05) EPS.
Several hedge funds and other institutional investors have recently made changes to their positions in AUPH. Macquarie Group Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the third quarter valued at about $26,000. Selective Wealth Management Inc. acquired a new position in Aurinia Pharmaceuticals during the third quarter worth about $33,000. BNP Paribas Arbitrage SA acquired a new position in Aurinia Pharmaceuticals during the third quarter worth about $40,000. Geneos Wealth Management Inc. raised its position in Aurinia Pharmaceuticals by 717.1% during the third quarter. Geneos Wealth Management Inc. now owns 2,108 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 1,850 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $45,000. Hedge funds and other institutional investors own 33.90% of the company’s stock.
Shares of AUPH traded down $0.43 during midday trading on Wednesday, reaching $11.85. The stock had a trading volume of 1,113,009 shares, compared to its average volume of 1,575,249. The company’s fifty day simple moving average is $13.38 and its two-hundred day simple moving average is $19.08. Aurinia Pharmaceuticals has a 1-year low of $9.72 and a 1-year high of $33.97.
About Aurinia Pharmaceuticals (Get Rating)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.